{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T18:06:14Z","timestamp":1788285974107,"version":"build-2803163510"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ygyno.2022.11.019","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T14:16:54Z","timestamp":1669731414000},"page":"1-3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Clinical commentary: Extra-uterine high-grade serous carcinoma: two pathways, two preventions?"],"prefix":"10.1016","volume":"169","author":[{"given":"Christopher P.","family":"Crum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Yoon","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen M.","family":"Feltmate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2022.11.019_bb0005","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1126\/science.1251900","article-title":"\u201cThe race\u201d to clone BRCA1","volume":"343","author":"King","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2022.11.019_bb0010","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.296.2.185","article-title":"Hereditary ovarian cancer clinical study group. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation","volume":"296","author":"Finch","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2022.11.019_bb0015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1006\/gyno.1999.5623","article-title":"Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations","volume":"76","author":"Zweemer","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.11.019_bb0020","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1097\/01.AOG.0000187892.78392.3f","article-title":"BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?","volume":"106","author":"Cass","year":"2005","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2022.11.019_bb0025","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.pas.0000180854.28831.77","article-title":"The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome","volume":"30","author":"Medeiros","year":"2006","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ygyno.2022.11.019_bb0030","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/PGP.0b013e31823b8831","article-title":"Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma","volume":"31","author":"Vang","year":"2012","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.ygyno.2022.11.019_bb0035","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1200\/JCO.21.02016","article-title":"Risk of peritoneal carcinomatosis after risk-reducing salpingo-oophorectomy: a systematic review and individual patient data meta-analysis","volume":"40","author":"Steenbeek","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.11.019_bb0040","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/PAS.0000000000000369","article-title":"Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma","volume":"39","author":"Howitt","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ygyno.2022.11.019_bb0045","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41588-019-0576-7","article-title":"Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing","volume":"52","author":"Cort\u00e9s-Ciriano","year":"2020","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ygyno.2022.11.019_bb0050","first-page":"108269","article-title":"Long-term tumour dormancy in a BRCA1 heterozygote","author":"Amuzu","year":"2022","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ygyno.2022.11.019_bb0055","doi-asserted-by":"crossref","first-page":"E466","DOI":"10.9778\/cmajo.20210219","article-title":"Opportunistic salpingectomy between 2011 and 2016: a descriptive analysis","volume":"10","author":"Hanley","year":"2022","journal-title":"CMAJ Open."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822019539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822019539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:02:15Z","timestamp":1758772935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825822019539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":11,"alternative-id":["S0090825822019539"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.11.019","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical commentary: Extra-uterine high-grade serous carcinoma: two pathways, two preventions?","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.11.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}